SHANGHAI, April 9, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the first cohort of healthy volunteers has been dosed in a phase I clinical trial of AK0406, a novel long-acting antiviral drug-Fc conjugate (ADFC) drug for influenza...
Hence then, the article about arkbio completed dosing of first cohort in australian phase i trial of antiviral drug fc conjugate drug ak0406 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( ArkBio Completed Dosing of First Cohort in Australian Phase I Trial of Antiviral Drug-Fc Conjugate Drug AK0406 )
Also on site :
- Mary-Kate and Ashley Olsen Started a Clothing Line in 2006 With a Simple White T-Shirt; 18 Years Later, Their Luxury Fashion Brand Was Valued at $1 Billion
- Macy’s Has Adorable Scalloped Bedding Sets for Up to 70% Off, and They’re Perfect for Fall Bedroom Refreshes
- ‘Saiyaara’ Star Ahaan Panday and Sharvari’s Ali Abbas Zafar Romantic Action-Drama for Yash Raj Films Unveils Title (EXCLUSIVE)